Celcuity https://validator.w3.org/feed/docs/rss2.html Block Pam. Unlock Tomorrow Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call Celcuity to Participate in the Cowen 42nd Annual Health Care Conference Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023 Celcuity to Participate in Cowen’s 43rd Annual Health Care Conference Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium Celcuity Closes $100 Million Private Placement Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023 Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Celcuity Set to Join Russell 2000 and 3000 Indexes Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023 Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences Celcuity Inc. Announces $50 Million Private Placement Celcuity to Host Virtual Science Day for Investors Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer Celcuity Appoints Eldon Mayer as Chief Commercial Officer Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference Celcuity To Present at Upcoming Needham and Stifel Investor Conferences